** PLEASE FOLLOW RUBRIC ATTACHED IN FILES!***
*SCREENSHOT OF INSTRUCTIONS IN FILES!!**
This Ais designed to help you analyze the many considerations for prescribing mood stabilizers, as well as organizing the many different lab components to consider when prescribing to a patient.
Directions:
Construct a 5- to 6-p p discussing each of the four traditional mood stabilizer medications: carbamazepine, lamotrigine, lithium, and valproate products. Support your answers with five (5) evidence-based, peer-reviewed scholarly literature.
Note: A P A style format will apply.
Your p should include the following for each:
- Proposed mechanism of action
- Baseline assessment, laboratory considerations, and frequency of ongoing labs and assessments
Note: Discuss the importance of assessment and labs. - Special population considerations (birth assigned gender, age, other medical comorbidity considerations)
- FDA approval indications
- Typical dosing with discussion on therapeutic endpoints for psychiatric use
- Major drug–drug interaction considerations
- For each of these medications, please review potential drug–drug interactions listed below. Consider alternative dosing schedules, clinical implications for the drug interactions, additional patient education needed, any additional monitoring recommended, or collaboration needed with other medical professions (such as, primary care providers)
- Lamotrigine + Valproate
- Lamotrigine + Rifampin
- Valproate + Estrogen containing birth control.
- Valproate + Amitriptyline
- Lithium + Furosemide
- Lithium + Lisinopril
- Carbamazepine + Lurasidone
- Carbamazepine + Grapefruit juice
- Discuss the ethical, legal, and social implications related to prescribing bipolar and other related mood-disorder diagnoses therapy for patients.
- For each of these medications, please review potential drug–drug interactions listed below. Consider alternative dosing schedules, clinical implications for the drug interactions, additional patient education needed, any additional monitoring recommended, or collaboration needed with other medical professions (such as, primary care providers)
Required readings:
- Goldin, D. S. (2023). Fast facts for psychopharmacology for nurse practitioners. Springer Publishing.
- Chapter 8, “Mood Stabilizers“ (pp. 150—178)
- Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
- Chapter 6, “Mood Disorders and the Neurotransmitter Networks Norepinephrine and y-Aminobutyric Acid (GABA)” (pp. pp. 244—282)
- American Psychiatric Association. (2010). Practice guideline for the treatment of patients with bipolar disorderLinks to an external site. (2nd ed.). APA. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
- Drugs.comLinks to an external site.. (2023). https://www.drugs.com/
Note: Please use the following resource to check the most up-to-date box warnings, FDA approvals and indications, recommendations for follow-up evaluations, changes, etc. - Approved Medications for Bipolar and Related Mood Disorders
Note: Utilize the following medication table to familiarize yourself with the medications aligned with the topics presented this week.
